speedy/RINGO cell cycle regulator family member E20, pseudogeneGenealiases: []
Q-omics provides the consensus-scored SPDYE20P profile across patient tissues and cancer cell-line models. SPDYE20P expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, SPDYE20P is differentially expressed in 3, with the highest sampling consensus in THCA. Additionally, SPDYE20P RNA expression shows 13,648 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, THCA, and UVM as cancer lineages where SPDYE20P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPDYE20P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPDYE20P survival associations across molecular data types. SPDYE20P RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPDYE20P RNA expression–survival associations across cancer types. High SPDYE20P expression shows unfavorable associations in KIRC, THCA, SARC, LIHC and ACC, but favorable associations in HNSC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify HNSC as the clearest survival context for SPDYE20P RNA expression.
This table summarizes SPDYE20P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for SPDYE20P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPDYE20P shows lower tumor expression in THCA and higher tumor expression in LUSC and COAD. The THCA box plot shows higher SPDYE20P RNA expression in normal versus tumor tissue (log2 FC = −0.096, t-test p < 0.001).
This table shows molecular features associated with SPDYE20P in patient tissues and cancer cell lines. In patient samples, SPDYE20P shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
